ResearcherXuzhou Medical CollegeActive in the last 2 years
Yu Ma
Matched on ORCID iD 0000-0003-2175-3346; OpenAlex author ID A5024037041. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 6
- Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma. Co-author DOI 10.3389/fphar.2024.1332042↗
- Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism. Co-author DOI 10.3390/ijms23126697↗
- Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.03.137↗
- CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
- Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2. Co-author DOI 10.3892/ol.2019.10551↗
- AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis. Co-author DOI 10.7150/jca.28299↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Peilin Huang · 6 shared papers, 2019–2024 · strength 0.85
- Paper Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma. DOI 10.3389/fphar.2024.1332042↗
- Paper Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF… DOI 10.3390/ijms23126697↗
- Paper Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal … DOI 10.1016/j.bbrc.2020.03.137↗
- Mingyue Hu · 5 shared papers, 2019–2022 · strength 0.60
- Paper Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF… DOI 10.3390/ijms23126697↗
- Paper Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal … DOI 10.1016/j.bbrc.2020.03.137↗
- Paper Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokina… DOI 10.3892/ol.2019.10551↗
- Bo Kong · 5 shared papers, 2019–2022 · strength 0.60
- Paper Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF… DOI 10.3390/ijms23126697↗
- Paper Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal … DOI 10.1016/j.bbrc.2020.03.137↗
- Paper Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokina… DOI 10.3892/ol.2019.10551↗
- Sunkai Ling · 4 shared papers, 2019–2022 · strength 0.51
- Paper Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF… DOI 10.3390/ijms23126697↗
- Paper Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal … DOI 10.1016/j.bbrc.2020.03.137↗
- Paper Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokina… DOI 10.3892/ol.2019.10551↗
- Shoucui Gao · 1 shared paper, 2024 · strength 0.26
- Hui Liu · 1 shared paper, 2022 · strength 0.17
- Yuan Li · 1 shared paper, 2020 · strength 0.13
- Zipeng Lu · 1 shared paper, 2020 · strength 0.10
- Shanshan Shen · 1 shared paper, 2020 · strength 0.10
- Kuirong Jiang · 1 shared paper, 2020 · strength 0.10
- Xiaoping Zou · 1 shared paper, 2020 · strength 0.10
- Yuan Li · 1 shared paper, 2019 · strength 0.09
- Yuhui Jiang · 1 shared paper, 2019 · strength 0.09
- Jiajia Xu · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.